Genflow Biosciences Plc (GB:GENF)
LSE:GENF
Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.25 p
-0.02 p(-1.09%)
At close: 4:00 PM EST
2.25 p
-0.02 p(-1.09%)
Day’s Range― - ―
52-Week Range0.55 p - 3.12 p
Previous CloseN/A
Volume13.76K
Average Volume (3M)1.73M
Market Cap
£11.47M
Enterprise Value11.62M
Total Cash (Recent Filing)£279.44K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial Debt (low Refinancing Risk)Having zero financial debt materially reduces refinancing risk for an early‑stage biotech. This gives management durable flexibility on timing and structure of external raises, supports continuing R&D investment between rounds, and lowers short‑term solvency pressure despite losses.
Focused Gene‑based Ageing Therapy PlatformA clear, focused R&D mandate on ageing and gene‑based approaches aligns with long‑term structural trends (aging populations, growing demand for age‑related therapeutics). A concentrated scientific niche can create durable differentiation and attract specialized partners or grant funding.
Signs Of Improving Cash And Loss Trends In 2025Measured improvements in free cash flow and reduced net losses in 2025 indicate incremental operational progress. While still cash negative, positive trend momentum can extend runway, reduce near‑term funding stress, and signal management is tightening spend or improving program efficiency.
Bears Say
Pre‑revenue With Persistent Operating LossesBeing pre‑revenue and loss‑making is a fundamental constraint: no internal product cash inflows means R&D and operating costs must be funded externally. Persistent losses erode flexibility and increase the probability of dilution or program delays until commercialization is demonstrably feasible.
Shareholders' Equity Turned NegativeNegative shareholders' equity reflects accumulated losses that have overwhelmed the capital base. This is a durable balance sheet weakness that constrains borrowing options, can complicate partner negotiations, and raises the likelihood that future funding will be dilutive or conditional.
Consistent Negative Operating And Free Cash FlowMulti‑year cash burn means the business is structurally dependent on external financing. That persistent funding dependency increases execution risk: program continuity, hiring, and clinical progress hinge on successful raises or partnerships rather than internal cash generation.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.55 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £11.47M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 96 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc is a biotechnology firm dedicated to devising biological treatments aimed at confronting the impacts of aging. Their goal is to slow down or completely stop the aging process and reduce the frequency of age-related illnesses, thereby extending the period of good health (healthspan). Their primary therapeutic asset is GF-1002, an adeno-associated viral vector-based gene therapy delivered through intravenous infusion. The company's pipeline also features GF-3001, a topical application of SIRT6 for skin treatment, and GF-4001, an anti-aging solution developed for veterinary use in non-human animals. Established in 2021, Genflow Biosciences plc is headquartered in London, United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---